menu
    • menu

    Company profile for Urovant Sciences

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigationa...
    Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Urovant SciencesSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Viaduktstrasse 8 4051 Basel
    Telephone
    Telephone
    41 61 225 44 82
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://urovant.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Urovant Announces Collaboration with Holly Robinson Peete for Overactive Bladder
    Urovant Announces Collaboration with Holly Robinson Peete for Overactive Bladder

    19 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230118005908/en

    BUSINESSWIRE
    19 Jan 2023
    Share Share
    Urovant launches overactive bladder awareness campaign
    Urovant launches overactive bladder awareness campaign

    17 Nov 2022

    // FIERCEPHARMA

    https://www.fiercepharma.com/marketing/urovant-launches-overactive-bladder-awareness-campaign-holiday-travel-season

    FIERCEPHARMA
    17 Nov 2022
    Share Share
    Urovant Sciences Announces Partnership with Thinx Inc.
    Urovant Sciences Announces Partnership with Thinx Inc.

    14 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221114005347/en

    BUSINESSWIRE
    14 Nov 2022
    Share Share
    Urovant Announces Publication of Pharmacokinetic Data on GEMTESA
    Urovant Announces Publication of Pharmacokinetic Data on GEMTESA

    27 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221027005843/en

    BUSINESSWIRE
    27 Oct 2022
    Share Share
    The Impact of Urinary Incontinence Related to Overactive Bladder
    The Impact of Urinary Incontinence Related to Overactive Bladder

    13 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220713005158/en

    BUSINESSWIRE
    13 Jul 2022
    Share Share
    Urovant and Pierre Fabre Sign Excl. License Agreement to Commercialize Vibegron
    Urovant and Pierre Fabre Sign Excl. License Agreement to Commercialize Vibegron

    06 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220705005255/en

    BUSINESSWIRE
    06 Jul 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search